eTheRNA Immunotherapies
Etherna is a biotechnology company that develops RNA and lipid nanoparticle technology platforms for nucleic acid-based therapeutics.
$39M Series B+ ·
Led by Novalis LifeSciences · Source: startupintros.com
Total raised: $104.41M across 3 sourced rounds
All 3 rounds ↓Acquired by VValerio Therapeutics on for $35M (EUR 30,000,000) · Pulse 2.0.
Signals
eTheRNA Immunotherapies | 3908 days on the record
Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.
Funding rounds
- Source: Pulse 2.0
- Series B+ · $39M
NNovalis LifeSciences (lead),
EEQT Life Sciences,
FFund+,
GGrand Pharma,
KKenneth Chien,
OOmega Funds,
PPMV
Source: startupintros.com - Series B+ · $38.41M
BBNP Paribas Private Equity,
BBoehringer Ingelheim Venture Fund,
CChina Grand Pharmaceutical and Healthcare Holdings,
YYijing Capital
Source: startupintros.com - Series A · $27MSource: startupintros.com
- Website created
Founders and team
KT
Kris Thielemans FounderDR
Dirk Reyn CEOLL
Luc Lammens FinanceSM
Sonja Meirvenne CMC Regulatory LeadSH
Steffen Helmling Chief Business Officer
Investors
EEuropean Commission
- LLSP
Companies like eTheRNA Immunotherapies
PParticellaRRigernaSeed · Mar 2026
AAxelyfSeed · Oct 2026
MMana Bio$20M Seed · Oct 2023PPURMX Therapeutics
EEVis BiosciencePre Seed · Feb 2026
Other companies backed by Novalis LifeSciences
MMercy BioAnalytics$59M Series B+ · Sep 2025
OOri Biotech$100M Series B+ · Jan 2022
Novalis LifeSciences portfolio →
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/etherna-immunotherapies (get a free API key).